Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G et al.. Annals of neurology, 2011-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective Assess Aβ deposition longitudinally and explore its relationship with cognition and disease progression. Methods Clinical follow-up was obtained 20 ± 3 months after [¹¹C]Pittsburgh compound B (PiB)-positron emission tomography in 206 subjects: 35 with dementia of the Alzheimer type (DAT), 65 with mild cognitive impairment (MCI), and 106 age-matched healthy controls (HCs). A second PiB scan was obtained at follow-up in 185 subjects and a third scan after 3 years in 57. Results At baseline, 97% of DAT, 69% of MCI, and 31% of HC subjects showed high PiB retention. At 20-month follow-up, small but significant increases in PiB standardized uptake value ratios were observed in the DAT and MCI groups, and in HCs with high PiB retention at baseline (5.7%, 2.1%, and 1.5%, respectively). Increases were associated with the number of apolipoprotein E ε4 alleles. There was a weak correlation between PiB increases and decline in cognition when all groups were combined. Progression to DAT occurred in 67% of MCI with high PiB versus 5% of those with low PiB, but 20% of the low PiB MCI subjects progressed to other dementias. Of the high PiB HCs, 16% developed MCI or DAT by 20 months and 25% by 3 years. One low PiB HC developed MCI. Interpretation Aβ deposition increases slowly from cognitive normality to moderate severity DAT. Extensive Aβ deposition precedes cognitive impairment, and is associated with ApoE genotype and a higher risk of cognitive decline in HCs and progression from MCI to DAT over 1 to 2 years. However, cognitive decline is only weakly related to change in Aβ burden, suggesting that downstream factors have a more direct effect on symptom progression.
What this study adds
Evidence grade: Low
The record lists 206 participants. People with mild cognitive impairment and high amyloid progressed to Alzheimer's dementia far more often than those with low amyloid (67% vs 5%), and 25% of healthy controls with high amyloid developed impairment by 3 years. Reported effect size: 5.7%; 2.1%; 1.5%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., et al. (2011). Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Annals of neurology. https://doi.org/10.1002/ana.22248
Vancouver
Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Annals of neurology. 2011. doi:10.1002/ana.22248. PMID: 21280088.
BibTeX
@article{villemagne2011-21280088,
author = {Villemagne, V. L. and Pike, K. E. and Chételat, G. and Ellis, K. A. and Mulligan, R. S. and Bourgeat, P. and Ackermann, U. and Jones, G. and others},
title = {{Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease}},
journal = {Annals of neurology},
year = {2011},
doi = {10.1002/ana.22248},
pmid = {21280088},
url = {https://doi.org/10.1002/ana.22248}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results At baseline, 97% of DAT, 69% of MCI, and 31% of HC subjects showed high PiB retention.
- At 20-month follow-up, small but significant increases in PiB standardized uptake value ratios were observed in the DAT and MCI groups, and in HCs with high PiB retention at baseline (5.7%, 2.1%, and 1.5%, respectively).
- Increases were associated with the number of apolipoprotein E ε4 alleles.
- Progression to DAT occurred in 67% of MCI with high PiB versus 5% of those with low PiB, but 20% of the low PiB MCI subjects progressed to other dementias.
- Extensive Aβ deposition precedes cognitive impairment, and is associated with ApoE genotype and a higher risk of cognitive decline in HCs and progression from MCI to DAT over 1 to 2 years.
Why it matters
In 206 people (35 with Alzheimer's dementia, 65 with mild cognitive impairment, 106 healthy controls) given repeat amyloid PET scans about 20 months apart, amyloid rose slightly in the dementia and MCI groups and in healthy people who already had high amyloid, and the rise was associated with the number of APOE ε4 alleles. People with mild cognitive impairment and high amyloid progressed to Alzheimer's dementia far more often than those with low amyloid (67% vs 5%), and 25% of healthy controls with high amyloid developed impairment by 3 years. But the link between rising amyloid and cognitive decline was weak, and 20% of low-amyloid MCI patients developed other dementias, so a scan result is a risk signal, not a diagnosis. The study describes no treatment.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Participants206
- Effect size5.7%; 2.1%; 1.5%
- Evidence strengthLow
How this study scored 63/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Annals of neurology) |
| Journal's citation record | 3 / 4 | Annals of Neurology: journal h-index 437 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2011 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 206 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 835 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 49.1 citations a year over 17 year(s) since 2011 |
| Impact for its field and year | 6 / 6 | Cited 51.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 89 other studies in this library |
| Still being cited | 3 / 4 | Cited 86 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Christopher Cleon Rowe: h-index 100 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Pittsburgh: institution h-index 1,470 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 21280088) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 63 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.
Later studies that cite this one
89 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Genetics from nearby years
Also in Genetics
207 studies in the library are filed under Genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Genetics hub.